Canaccord lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $5 from $7 and keeps a Buy rating on the shares. The firm updated its model following the comany’s recent raise and renegotiated covenants. Importantly, they have also managed to renegotiate some financial covenants, and believes it has a cash runway into 1Q25. The refashioned agreements call for an additional amount to be raised over 1Q25 through some points in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics prices 5.6M shares at 48c in public offering
- Bioxcel Therapeutics Restructures Credit and Strengthens Leadership
- BioXcel announces common stock and warrants offering, no amount given
- BioXcel Therapeutics Reports Q3 2024 Financial Results
- BioXcel Therapeutics reports Q3 EPS (32c), consensus (48c)
Questions or Comments about the article? Write to editor@tipranks.com